Navigation Links
Freeslate Collaborates with Medicines for Malaria Venture to Advance Therapeutic for Treating Malaria

SUNNYVALE, Calif (PRWEB) May 30, 2013

Freeslate, Inc., the leading provider of high throughput research solutions, today announced outcomes following a pro-bono study with researchers from Rutgers University in New Jersey working with Medicines for Malaria Venture (MMV, to discover new antimalarial agents. Using Freeslate’s CM3 Reaction Screening System, an efficient and simple resolution process that achieves near 100 percent chiral resolution was identified after just two weeks of effort with the Freeslate system. In follow up work at the Rutgers laboratories, the process performed extremely well on multi-gram scale and efficiently provides sufficient material to move the program forward toward the possible identification of a clinical candidate for malaria.

Freeslate will be offering a free webinar on this important study on June 25, 2013 (visit to register).

"What remains amazing is the nature of the data generated by the Freeslate group using their CM3 system after just a couple of weeks of effort. It pointed to a process that immediately translated to gram and multi-gram scale. With only minor modifications, the data provided using the Freeslate system affords material with close to 100 percent chiral purity in near quantitative yield. Having worked on this problem in our laboratories for some time, it is clear we would not have been able to advance as quickly or at all without the collaboration with Freeslate," said David Floyd, a consultant with Medicines for Malaria Venture and Visiting Scientist at Rutgers University. "This procedure will allow us to efficiently prepare larger amounts of intermediate required to progress our program toward a possible clinical candidate.”

Malaria continues to cause over 600,000 deaths every year. MMV has a mission to reduce the burden of malaria in disease-endemic countries by discovering, developing, and facilitating delivery of new, effective, and affordable antimalarial drugs.

In March 2013, the researchers began working with Freeslate to leverage very preliminary data from the Rutgers labs using the Freeslate CM3 Reaction Screening System, an automated and configurable robotic platform that enables users to perform high-throughput process research and development (PRD). The research conducted on the System quickly provided the Rutgers researchers with conditions that, when scaled-up, proved to be simple, extremely efficient, and potentially cost-effective – a very important component to success with the discovery of new treatments for malaria.

“We were extremely excited about the opportunity to be a part of advancing this important malaria research program and are pleased that our existing product could contribute to their efforts in such a significant manner,” said John S. Senaldi, President and CEO of Freeslate. “The ability to go from preliminary work to a potentially scalable process in just two weeks demonstrates the true innovation and efficiency that our platform offers.”

With the CM3-based Reaction Screening System users can screen hundreds of experimental conditions per day under a variety of composition variables (e.g., acids, bases, counterions, catalysts, ligands, solvents) and under a variety of conditions (e.g., temperature, pressure, concentration, equivalents) to quickly optimize process parameters using minimal amounts of materials. Because of the greater throughput, users can explore experimental parameters outside those used in conventional approaches, reducing development risk, and allowing for non-intuitive discoveries.

About Freeslate

Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, and energy industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
2. Elsevier Collaborates with the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)
3. Elsevier Collaborates With Prophecy Healthcare to Enhance Its Staff Development Offerings for Healthcare Organizations
4. Goddard collaborates with international partners on MMS instrument
5. Ambrx Collaborates with Merck to Design and Develop Biologic Drug Conjugates
6. uniQure Collaborates with UCSF on GDNF Gene Therapy in Parkinsons Disease
7. Genetics Policy Institute (GPI) Collaborates on Second Midwest Conference on Stem Cell Biology and Therapy, Oct. 5-7 at Oakland University
8. Elsevier Collaborates With Infocomm Development Authority of Singapore and Top Academic Institutions to Bring CodeForScience to Singapore
9. DuPont Collaborates with Agricultural Educators to Reach More Students
10. DuPont Tate & Lyle Bio Products Collaborates with RML Incorporated to Develop Bio-Based Solution for Personal Care Products
11. Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway
Post Your Comments:
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... 2016 adds 2016 ... its pharmaceuticals section with historic and forecast data ... more. Complete report on the Cell ... 15 companies and supported with 261 tables and ... . The Global Cell Culture Media ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/15/2016)... -- A new partnership announced today will help life ... a fraction of the time it takes today, ... insurance policies to consumers without requiring inconvenient and ... rapid testing (A1C, Cotinine and HIV) and higi,s ... pulse, BMI, and activity data) available at local ...
Breaking Biology News(10 mins):